An observational study in Critical Illness, Sepsis and Hyperferritinemia, sponsored by Charles University, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Charles University, Czech Republic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Sepsis with a site in Czechia — 4 open to participants now, 5 under way, none of them phase 3. Sepsis · Czechia.
Among the 28 studies in Sepsis with a site in Czechia, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, and was the 26th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →4 of the 28 studies in Sepsis with a site in Czechia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Czechia, United States, Argentina and 11 more countries
Ages 18–80
University Hospital Ostrava · Sites in Czechia
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18+ · Healthy volunteers
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,962 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 289 across the 16 interventional studies, 200 across the 11 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Charles University, Czech Republic has 4 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Sepsis with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Analysing trajectory of critically ill patients with signs of hyperinflammation
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's planned enrollment of 1,962 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Browse Sepsis studies →Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
critically ill patients; mix-cases medical ICU population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
critically ill patients admitted to ICU between 01.01.2020 and 31.12.2024
hyperferritinemia
trajectory of critically ill patients with significant hyperferritinemia and with regard to its dynamics; ferritin value cutt-off
Time frame: 2025
etiology and association of hyperferritinemia
etiology and association of hyperferritinemia with infectioius a non-infectious diseases/conditions
Time frame: 2025
mortality a morbidity
mortality a morbidity of patients with significant hyperferritinemia
Time frame: 2025
treatment strategy
association of hyperferritinemia and treatment strategy
Time frame: 2025
stratification
patient stratification according to hyperferritinemia/hyperinflammation
Time frame: 2025
Plan to share: Yes
Supporting information: Study protocol, Clinical study report
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Feb 2025 → Oct 2026, primary completion Jun 2025 → Dec 2027 and completion Nov 2025 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles University, Czech Republic →